Abpro Holdings, Inc.

Abpro Holdings, Inc., trading under the ticker ABP, is a biopharmaceutical company that filed a Form 10-Q with the SEC on May 20, 2022, under accession number 0001193125-22-156322, reflecting its status as an active reporting company at that time. Operating within the life sciences and biotechnology sector, Abpro focuses on antibody-based therapeutic development. The company's 2022 quarterly filing captures a period of active operational and financial disclosure consistent with post-listing reporting obligations. As of the filing date, ABP remained subject to standard SEC periodic reporting requirements. For full filing history, current status, and deeper data on ABP and hundreds of other SPAC-linked securities, sign up for SpacDesk.